AstraZeneca/Daiichi Sankyo ADC Pact Continues Clinical Success In Breast Cancer

Early TNBC Efficacy Signs From Datopotamab Deruxtecan

 
• By Alaric DeArment
  
Generate a summary of this article
Listen to this article
Beta

While much earlier in its development, the drug may be able to rival Gilead’s Trodelvy, which also targets TROP2 and showed similar response rates.

Doctor with Mammography - Image
AstraZeneca/Daiichi Sankyo's datopotamab deruxtecan shows early efficacy in triple-negative breast cancer • Source: Shutterstock

Early efficacy data for AstraZeneca PLC and Daiichi Sankyo Co., Ltd.’s antibody-drug conjugate (ADC) datopotamab deruxtecan in triple-negative breast cancer may bolster the drug’s position as a worthy successor to the two companies’ previously approved ADC, as well as a potential competitor against an approved Gilead Sciences, Inc. drug with the same target that has produced similar response rates.

The partners unveiled new data on 8 May from the triple-negative breast cancer (TNBC) cohort of the Phase I TROPION-PanTumor01...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

  • Sciwind Eyes Differentiation For Ecnoglutide In Highly Competitive Arena

     
    • By Xu Hu

    Chinese firm Sciwind has revealed additional Phase III findings for its promising once-weekly GLP-1 agonist ecnoglutide, just one asset in a burgeoning Chinese sector that could see the emergence of new rivals to current global leaders in obesity and diabetes.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

     
    • By Xu Hu

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

  • Sponsored By:

    Nancy Tests SPARC-931-part

    The article discusses the impact of upcoming patent expirations in oncology biologics on biosimilar developers, highlighting the opportunities in Antibody-Drug Conjugates (ADCs) and Bispecific Antibodies (BsAbs). It explores the challenges posed by the structural complexities of these biologics, necessitating new bioanalytical tools and manufacturing processes. The evolving regulatory landscape, with contributions from EMA, FDA, and WHO, offers flexible pathways but also presents challenges. The article underscores the potential for biosimilars to generate significant cost savings and enhance patient access to cancer treatments over the next decade.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

More from R&D